CN101195048A - Compound medicament washing bracket and method for preparing the same - Google Patents
Compound medicament washing bracket and method for preparing the same Download PDFInfo
- Publication number
- CN101195048A CN101195048A CNA2006101193257A CN200610119325A CN101195048A CN 101195048 A CN101195048 A CN 101195048A CN A2006101193257 A CNA2006101193257 A CN A2006101193257A CN 200610119325 A CN200610119325 A CN 200610119325A CN 101195048 A CN101195048 A CN 101195048A
- Authority
- CN
- China
- Prior art keywords
- medicine
- bracket
- eluting medicament
- estradiol
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title abstract description 25
- 238000005406 washing Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 229940011871 estrogen Drugs 0.000 claims abstract description 16
- 239000000262 estrogen Substances 0.000 claims abstract description 16
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 7
- 230000002785 anti-thrombosis Effects 0.000 claims abstract description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 57
- 229960005309 estradiol Drugs 0.000 claims description 57
- 229930182833 estradiol Natural products 0.000 claims description 57
- 238000000576 coating method Methods 0.000 claims description 47
- 239000011248 coating agent Substances 0.000 claims description 41
- 229920000642 polymer Polymers 0.000 claims description 21
- 208000037803 restenosis Diseases 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 11
- 238000013508 migration Methods 0.000 claims description 9
- 230000002980 postoperative effect Effects 0.000 claims description 9
- 230000000975 bioactive effect Effects 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002131 composite material Substances 0.000 claims description 6
- 230000001028 anti-proliverative effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 230000001680 brushing effect Effects 0.000 claims description 4
- 238000003618 dip coating Methods 0.000 claims description 4
- 229960001348 estriol Drugs 0.000 claims description 4
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 4
- 229960002568 ethinylestradiol Drugs 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 230000002599 biostatic effect Effects 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 239000003610 charcoal Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 3
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 claims description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 229920002292 Nylon 6 Polymers 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004642 Polyimide Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 239000000560 biocompatible material Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229920006237 degradable polymer Polymers 0.000 claims description 2
- 238000001212 derivatisation Methods 0.000 claims description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 2
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 229950002007 estradiol benzoate Drugs 0.000 claims description 2
- 229960004766 estradiol valerate Drugs 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- 229930003944 flavone Natural products 0.000 claims description 2
- 150000002212 flavone derivatives Chemical class 0.000 claims description 2
- 235000011949 flavones Nutrition 0.000 claims description 2
- 229920002313 fluoropolymer Polymers 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 2
- 235000008696 isoflavones Nutrition 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 150000005217 methyl ethers Chemical class 0.000 claims description 2
- 229950007863 nilestriol Drugs 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- -1 polydimethylsiloxane Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 239000007769 metal material Substances 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 229910052715 tantalum Inorganic materials 0.000 claims 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 9
- 208000007536 Thrombosis Diseases 0.000 abstract description 8
- 230000035876 healing Effects 0.000 abstract description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 2
- 238000010828 elution Methods 0.000 abstract 3
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 34
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 33
- 229960002930 sirolimus Drugs 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 229930012538 Paclitaxel Natural products 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 229960001592 paclitaxel Drugs 0.000 description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 14
- 229960003957 dexamethasone Drugs 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 229920000747 poly(lactic acid) Polymers 0.000 description 7
- 239000004626 polylactic acid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 244000309715 mini pig Species 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 239000013595 supernatant sample Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000005543 nano-size silicon particle Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VRBFTYUMFJWSJY-UHFFFAOYSA-N 28804-46-8 Chemical compound ClC1CC(C=C2)=CC=C2C(Cl)CC2=CC=C1C=C2 VRBFTYUMFJWSJY-UHFFFAOYSA-N 0.000 description 1
- SJUWEPZBTXEUMU-LDXVYITESA-N 7-bromo-6-chloro-3-[3-[(2s,3r)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide Chemical compound Br.O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 SJUWEPZBTXEUMU-LDXVYITESA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 206010007687 Carotid artery stenosis Diseases 0.000 description 1
- 206010061751 Cerebrovascular stenosis Diseases 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940098704 Heparin inhibitor Drugs 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- PYFNMTXVGCHGMU-UHFFFAOYSA-N chloromethylbenzene;pyridine Chemical compound C1=CC=NC=C1.ClCC1=CC=CC=C1 PYFNMTXVGCHGMU-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011977 dual antiplatelet therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 description 1
- 229940095529 heparin calcium Drugs 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 230000008069 intimal proliferation Effects 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229950003837 ozagrel Drugs 0.000 description 1
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001693 poly(ether-ester) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a compound drug elution cardiovascular stent and preparing process, and the drug elution stent of the invention adopts the drug combination of estrogen biological active drug and coagent. After the compound drug elution cardiovascular stent is implanted in a vivo lumen, the continuous release of drugs carried by the cardiovascular stent is used for inhibiting the smooth muscle cells from bleeding and extracellular stroma from synthesizing, simultaneously, the healing of injured vessel walls can be improved, the late thrombus is prevented, and the economic burden of intake of antithrombotic and platelet drugs is reduced after the operation is carried out to the patient.
Description
[technical field]
The present invention relates to a kind of combination drug coating bracket, belong to the medical apparatus and instruments scope.
[background technology]
There is the millions of people in the whole world because suffer from the narrow class disease of cardiovascular of atherosis class every year, accept percutaneous arteria coronaria plasty (PTCA) and support and implant the vascular interventional treatment of modes such as (stent) art, the greatest problem that is perplexing these interventional therapys is the restenosis problem of postoperative, according to statistics, the PTCA postoperative has 50%, and 20～30% patient behind the Stent is because vascular restenosis needs interventional therapy or surgical operation therapy once more.Select the medicine of blocking-up restenosis generating process, it be coated on rack surface, be implanted to the vascular lesion position after, medicine is local to be discharged, performance suppresses the intimal proliferation effect, is the main direction of present anti-restenosis research.The coating medicine that adopts comprises the medicine of immunosuppressant, anti-inflammatory drug, anti-smooth muscle proliferation and migration medicine and promotion endothelial cell proliferation and migration etc. at present.
Up to the present, bracket for eluting medicament by the U.S. FDA authentication has only the rapamycin FirebirdTM (CYPHER) of Cordis company and the paclitaxel FirebirdTM (TAXUS) of Boston science and technology, clinical use has very strong anti-restenosis effect, and patient's restenosis rate drops in 10% over the past half year.But because rapamycin and paclitaxel do not have selectivity for vascular endothelial cell and smooth muscle cell, in the strong inhibition vascular smooth muscle cell, propagation and migration that also can the strong inhibition endotheliocyte, endothelialization postpones after causing stenting, this is the main cause that causes bracket for eluting medicament postoperative advanced thrombus, height is disabled, high mortality because the present advanced thrombus that is caused by drug stent has, and is just causing increasing concern.
Accelerating bracket for eluting medicament and implant the early stage reparation of back damage endothelium, avoid the generation of endothelialization delay phenomenon at least, recover the endothelium normal physiological function, is the key that prevents that stent thrombosis from forming, and also is the important directions of present bracket for eluting medicament research.Promote the measure of support endothelialization to mainly contain two aspects, the one, promote migration, the propagation of local endotheliocyte, the 2nd, promote in the circulation endothelial progenitor cells to gather and break up partial.Reported the KAT-II clinical trial of topical application VEGF (VEGF) adenovirus and plasmid safety and feasibility in the human body coronary artery in 2003, but can not give up the misgivings of people to its safety, and the coronarography inspection is not observed it and can be reduced in-stent restenosis (Circulation after June, 2003,107:2677-2683), moreover the technology of preparing complexity, feasibility is relatively poor.The clinical trial HEALING-FIM registration studies that the interior application of human body in 2005 can be captured the anti-CD34 antibody coating support of endothelial progenitor cells shows, radiography was followed up a case by regular visits to and was shown that tube chamber was lost the luminal stenosis rate that shows with IVUS and compared with bare bracket and there is no significant advantage (J Am Coll Cardiol late period June, 2005,45:1574-1579), its main defective is anti-CD34 antibody behind the bracket coating activity is difficult to preserve.
Estrogen is the endogenous hormone medicine that a class has the cardiovascular protection effect, can promote the partial endothelialization of injured blood vessel, suppresses propagation, migration and the blood vessel negativity of vascular smooth muscle cell and reinvents, and suppresses the partial inflammatory reaction of blood vessel.Zoopery shows that estrogen can improve the nitricoxide synthase at endothelial injury position (eNOS) level, strengthen the fixing and differentiation (Circulation.2003 of circulation endothelium progenitor cell in the blood, 107 (24): 3059-65), estradiol FirebirdTM clinical trial (EASTER) shows that it is safe and feasible (J Am Coll Cardiol.2004 that the estradiol support is used for human body, 43 (6): 1118-21), but its anti-restenosis effect is not also determined.
The estrogen biologically active drug that has that will have antithrombotic or antiproliferative anti-restenosis medicaments and promotion support endothelialization combines, prepare compound bracket for eluting medicament, make it when preventing thrombosis formation, keeping powerful anti-restenosis effect, and has an early stage support endothelialization, be expected to solve simultaneously restenosis and endothelialization and postpone two large problems, important clinic value is arranged.
The present invention uses the employing composite drug-eluting stent, to have bioactive medicine of estrogen and coagent and unite use, be applied to the intravascular stent surface, it is discharged by the certain hour order, it is synthetic to suppress smooth muscle cell proliferation and extracellular matrix, can promote simultaneously the healing of injured blood vessel wall, prevent the generation of advanced thrombus, reduce the financial burden that patient's postoperative is taken antithrombotic and platelet medicine.
[summary of the invention]
The present invention relates to be used to prevent and treat a kind of bracket for eluting medicament of the narrow property of cardiovascular disease, belong to the scope of medical apparatus and instruments.
Order of the present invention is on bracket for eluting medicament to adopt estradiol etc. to have the combination of the optional a kind of and coagent of the bioactive medicine of estrogen, is used for the narrow property of cardiovascular treatment of diseases.The generation of prevention of postoperative restenosis phenomenon also promotes the support process of endothelialization again.
The narrow property of cardiovascular disease, comprise heart and peripheral arterial because the narrow and acute obturation that atherosclerotic plaque forms and acute thrombus causes, as coronary stricture, cerebrovascular stenosis, carotid artery stenosis, iliac artery is narrow and shareholder's arteries and veins is narrow etc.
Have been found that now estradiol has the effects such as mobilization differentiation that promote the endothelial cell proliferation migration, promote endothelial progenitor cells (EPC) in the blood, can promote the process of endothelialization again of damaged part behind the cardiovascular interventional procedure.In addition, estradiol can also suppress the propagation of vascular smooth muscle cell, has certain anti-restenosis effect.Yet, use the estradiol FirebirdTM still to have higher restenosis separately and take place.
Estradiol etc. had the bioactive medicine of estrogen, optional a kind of and coagent such as anti-proliferative drugs united use preparation composite drug-eluting stent, can be used for the narrow property of cardiovascular treatment of diseases, the generation of prevention of postoperative restenosis phenomenon also promotes the support process of endothelialization again.
According to the present invention, estradiol etc. have the bioactive medicine of estrogen, and a kind of and one or more that can choose wantonly are selected from following coagent and share: immunosuppressant and anti-inflammatory drug, antithrombotic and anticoagulant, antiproliferative agents medicine, short endothelialization medicine again, anti-migration medicine and intercellular matrix regulator.
Of the present invention have a bioactive medicine of estrogen, the estrogen such as estradiol, estriol, estrone, estradiol benzoate, estradiol valerate, dipropionate estradiol, nilestriol, ethinylestradiol, female three methyl ethers of alkynes, ethinylestradiol methyl ether, diethylstilbestrol and structural derivative and the analog that comprise natural half-natural source, semi-synthetic and synthetic, comprise that also plant origin has the medicine of estrogen activity, as resveratrol, soybean isoflavone, Radix Puerariae flavone and structural derivative thereof and analog.
Immunosuppressant of the present invention is including, but not limited to rapamycin, tacrolimus, everolimus, ABT-578, mycophenolate and cyclosporin, interferon, mizoribine and leflunomide etc.
Anti-inflammatory agent of the present invention is including, but not limited to corticosteroid, such as prednisone, meticortelone, dexamethasone, prednisone and cortisone etc.; Comprise NSAID (non-steroidal anti-inflammatory drug), such as celecoxib, rofecoxib, aspirin etc.; Comprise ascosin, such as pimecrolimus etc.; Also comprise cytokine inhibitor.
Antiproliferative agents of the present invention is including, but not limited to taxanes, vinca alkaloids, Epothilones and derivant thereof, tyrosine kinase inhibitor and with receptors bind such as PDGF, EGF, VEGF or reduce the medicine of its expression.
Antithrombotic of the present invention and anticoagulant are including, but not limited to clopidogrel, low molecular heparin calcium, Lumbrukinase, low molecular sodium heparin, sodium ozagrel, alteplase enzyme, Enoxaparin Sodium, benzyl chloride pyridine, cilostazol, heparin sodium, hirudin, urokinase, heparin and glycoprotein iib/iiia inhibitor etc.
Short endothelialization medicine more of the present invention is including, but not limited to BCP671, VEGF, G-CSF, endothelial progenitor cells antibody and nitric oxide donors etc.
Anti-migration medicine of the present invention and intercellular matrix regulator are including, but not limited to batimastat, marimastat, probucol, C-protease inhibitor, halofuginone hydrobromide and prolyl hydroxylase inhibitor.
Support be mixed or be attached to active medicine combination of the present invention can by several different methods and any biocompatible materials; Medicine can be dissolved in polymer and obtain medicine and mixture of polymers in single solvent or the mixed solvent, be applied to rack surface, treat to obtain being embedded in after the solvent evaporates medication coat of medicine by methods such as spraying, dip-coating, brushings; Medicine can be participated in the degradable polymer, adopt the preparation of heating and melting or other method to contain the degradable FirebirdTM of drug regimen; Medicine can be inserted in the shrinkage pool of rack surface; Medicine can be mixed in the coatings such as biocompatibility porous ceramics coating, the poly-charcoal of fluorine; Medicine can chemical bond arrive polymer or rack surface, relates to the method for chemical derivatization; In addition, the preparation polymer coating is adsorbed onto medicine in the coating more earlier, obtains containing the coating of medicine.The medication coat gross thickness of this bracket for eluting medicament is 1～100um, and wherein the shared percentage by weight of active medicine is 1～40%.
Drug regimen of the present invention, can be simultaneously and polymeric material be dissolved in single solvent or the mixed solvent, be applied to rack surface by methods such as spraying, dip-coating, brushings again, treat to obtain the monolayer medication coat that embedding medicinal makes up after the solvent evaporates; Can be dissolved in single solvent or the mixed solvent with polymeric material respectively,, be applied to rack surface successively by methods such as spraying, dip-coating, brushings again, treat to obtain the multilayer medicine coating that embedding medicinal makes up after the solvent evaporates.Can be in the outside of medicine layer, repaste cloth one deck does not contain the polymer coating of medicine, is used for controlling the drug release behavior of medication coat.In addition,, can be coated with the one layer of polymeric coating earlier,, be used to strengthen the bond strength of medication coat and metal support surface as parylene C in the inboard of medication coat.
Polymer of the present invention is a biocompatible polymer, comprises biodegradable polymer and Biostatic polymer.Wherein biodegradable polymer comprises collagen, hyaluronic acid, gelatin, polyester, polyamino acid, polysaccharide, polyphosphazene, poly-(ether-ester), copolymer or its mixture.Wherein Biostatic polymer comprises: polyurethanes, polyolefin, polyester, polyamide, polycaprolactam, polyimides, polyvinyl methyl ether, polyvinyl alcohol or vinyl alcohol, olefin copolymer, polyacrylonitrile, polydimethylsiloxane, poly-(ethane-acetic acid ethyenyl ester), based on the polymer of acrylate or copolymer, polyvinylpyrrolidone, fluorinated polymer, cellulose esters, or its mixture.
Support under the present invention, comprise that balloon expandable stent, self-expanding stent and other are used for the support of cardiovascular interventional therapy, can be by metal racks such as Nitinol, cobalt alloy, titanium alloy, stainless steel alloies, also can be the polymer support of making by polymeric material, as the polylactic acid bracket that can degrade fully etc.
It is estradiol that the present invention preferably has the bioactive medicine of estrogen, and carries out once more preferably obtaining the compound FirebirdTM of preferred rapamycin estradiol on the basis in view of the above.Adopting degradable polylactic acid is the compound FirebirdTM of degradable coating rapamycin of polymer support preparation, can stablize release-more than individual month external.And in the porcine coronary restenosis model, has good anti-restenosis and short rapamycin support endothelialization dual function again.
The present invention will solve behind current use rapamycin FirebirdTM and the paclitaxel FirebirdTM endothelialization delay issue again, quicken the repair process (promptly endothelialization process) again of endothelial injury behind the stenting, reduce thrombosis and the acute myocardial infarction of initiation and the risk of death in the support in late period, in addition, can also shorten the time that patient takes dual Antiplatelet therapy medicine, reduce the burden of patient's economy, have good clinical and commercial promise.
Following examples are used to set forth the present invention, but do not limit the present invention.
[description of drawings]
Accompanying drawing 1, rapamycin and estradiol measure the HPLC collection of illustrative plates (A, rapamycin sample, B, estradiol sample, C, handkerchief mycin and estradiol biased sample, 1, rapamycin peak 2, rapamycin isomer peak 3, estradiol peak)
Accompanying drawing 2, the compound FirebirdTM release in vitro of embodiment 1 rapamycin estradiol curve chart
Accompanying drawing 3, paclitaxel and estradiol measure the HPLC collection of illustrative plates (A, paclitaxel sample, B, estradiol sample, C, paclitaxel and estradiol biased sample, 1, paclitaxel peak 2, estradiol peak)
Accompanying drawing 4, the compound FirebirdTM release in vitro of embodiment 2 thunder paclitaxel estradiol curve chart
Accompanying drawing 6, the compound FirebirdTM release in vitro of embodiment 3 dexamethasone estradiol curve chart
Accompanying drawing 7, the compound FirebirdTM sem photograph of embodiment 1 rapamycin estradiol
Accompanying drawing 8, the compound FirebirdTM of rapamycin estradiol are implanted 30 days support vessel segment transverse section of miniature pig arteria coronaria section light microscopic figure
Accompanying drawing 9, rapamycin FirebirdTM are implanted 30 days support vessel segment transverse section of miniature pig arteria coronaria section light microscopic figure
Accompanying drawing 10, the compound FirebirdTM of rapamycin estradiol are implanted the sem photograph of 14 days miniature pig coronary artery bracket vessel segment endotheliocytes
Accompanying drawing 11, rapamycin FirebirdTM are implanted the sem photograph of 14 days miniature pig coronary artery bracket vessel segment endotheliocytes
[specific embodiment]
Take by weighing rapamycin and polylactic acid is an amount of, both percentage by weights are 3: 7, and obtaining percentage by weight with the dichloromethane ultrasonic dissolution is 1% coating liquid.The coating liquid atomizing spraying of preparation is arrived through pretreated bare metal stent surface.Again that support is dry under 60 ℃ and 0.1Mpa vacuum, prepare the rapamycin layer.Take by weighing estradiol and polylactic acid is an amount of, both percentage by weights are 2: 8, and obtaining percentage by weight with the dichloromethane ultrasonic dissolution is 1% coating liquid.Adopt aforementioned coating process that estradiol layer coating liquid is coated onto the drug stent surface that coats rapamycin layer coating, obtain the compound FirebirdTM of rapamycin estradiol.
Take by weighing paclitaxel and the polymethyl methacrylate nano silicon dioxide composite material is an amount of, both percentage by weights are 3: 7, and obtaining percentage by weight with the oxolane ultrasonic dissolution is 1% coating liquid.The coating liquid atomizing spraying of preparation is arrived through pretreated bare metal stent surface.Again that support is dry under 60 ℃ and 0.1Mpa vacuum, prepare the paclitaxel coating.Take by weighing estradiol and the polymethyl methacrylate nano silicon dioxide composite material is an amount of, both percentage by weights are 3: 7, and obtaining percentage by weight with the oxolane ultrasonic dissolution is 1% coating liquid.Adopt aforementioned coating process that estradiol layer coating liquid is coated onto the drug stent surface that coats paclitaxel layer coating, obtain the compound FirebirdTM of paclitaxel estradiol.
Take by weighing dexamethasone and poly-(ethane-acetic acid ethyenyl ester) in right amount, both percentage by weights are 4: 6, and obtaining percentage by weight with the oxolane ultrasonic dissolution is 1% coating liquid.The coating liquid atomizing spraying of preparation is arrived through pretreated bare metal stent surface.Again that support is dry under 60 ℃ and 0.1Mpa vacuum, prepare the paclitaxel coating.Take by weighing estradiol and poly-(ethane-acetic acid ethyenyl ester) material in right amount, both percentage by weights are 2: 8, and obtaining percentage by weight with the oxolane ultrasonic dissolution is 1% coating liquid.Adopt aforementioned coating process that estradiol layer coating liquid is coated onto the drug stent surface that coats dexamethasone layer coating, obtain the compound FirebirdTM of dexamethasone estradiol.
It is an amount of to take by weighing rapamycin, estriol and polylactic acid, and both percentage by weights are 1: 1: 3, and obtaining percentage by weight with the dichloromethane ultrasonic dissolution is 1% coating liquid.The coating liquid atomizing spraying of preparation is arrived through pretreated bare metal stent surface.Again that support is dry under 60 ℃ and 0.1Mpa vacuum, prepare rapamycin estriol layer.It is an amount of to take by weighing polylactic acid, and obtaining percentage by weight with the dichloromethane ultrasonic dissolution is 0.5% coating liquid.Adopt aforementioned coating process that polylactic acid coating liquid is coated onto the drug stent surface that coats rapamycin estradiol layer coating, obtain the compound FirebirdTM of rapamycin estradiol.
(methanol: 0.05MpH7.4PBS=20: 80) be medium, carry out the research of release in vitro degree in 37 ℃ of water bath chaders, frequency of oscillation is 100RPM with 10ml20% methanol will to prepare the compound FirebirdTM of rapamycin estradiol.Interval in accordance with regulations takes out whole media (staying 1ml is sample) and replenishes synthermal 20% methanol of equal-volume.Sample-20 is ℃ freezing, thaw before the mensuration and 15000rpm * 10min centrifugal, the supernatant sample introduction.Chromatographic condition: mobile phase: methanol: acetonitrile: water=27: 46: 27, λ=280nm, 55 ℃ of column temperatures, flow velocity=1ml/min.The HPLC chromatogram of rapamycin and estradiol such as accompanying drawing 1.The compound FirebirdTM release in vitro of the rapamycin estradiol curve of embodiment 1 preparation is seen accompanying drawing 2.
Embodiment 6
To prepare the compound FirebirdTM 10ml0.1%SLS of paclitaxel estradiol is medium, carries out the research of release in vitro degree in 37 ℃ of water bath chaders, and frequency of oscillation is 100RPM.Interval in accordance with regulations takes out whole media (staying 1ml is sample) and replenishes synthermal 20% methanol of equal-volume.Sample-20 is ℃ freezing, thaw before the mensuration and 15000rpm * 10min centrifugal, the supernatant sample introduction.Chromatographic condition: mobile phase: acetonitrile: water=50: 50, λ=230nm, 50 ℃ of column temperatures, flow velocity=1ml/min.The HPLC chromatogram of paclitaxel and estradiol such as accompanying drawing 3.The compound FirebirdTM release in vitro of the paclitaxel estradiol curve of embodiment 2 preparations is seen accompanying drawing 4.
Embodiment 7
(methanol: 0.05MpH7.4PBS=10: 90) be medium, carry out the research of release in vitro degree in 37 ℃ of water bath chaders, frequency of oscillation is 100RPM with 10ml10% methanol will to prepare the compound FirebirdTM of dexamethasone estradiol.Interval in accordance with regulations takes out whole media (staying 1ml is sample) and replenishes synthermal 20% methanol of equal-volume.Sample-20 is ℃ freezing, thaw before the mensuration and 15000rpm * 10min centrifugal, the supernatant sample introduction.Chromatographic condition: mobile phase: methanol: 0.02M sodium dihydrogen phosphate (pH4.0)=50: 50, λ
1=280nm; λ
255 ℃ of=230nm column temperatures, flow velocity=1ml/min.The HPLC chromatogram of dexamethasone and estradiol such as accompanying drawing 5.The compound FirebirdTM release in vitro of the dexamethasone estradiol curve of embodiment 3 preparations is seen accompanying drawing 6.
Embodiment 8
Adopt scanning electron microscope to carry out the observation of face coat form the compound FirebirdTM of the rapamycin estradiol of preparation.Can see that the rack surface coating of invention example 1 preparation is smooth smooth, the requirement of the clinical use mechanical performance of bracket for eluting medicament coating is satisfied in no obvious perk behind the balloon expandable, situation generation (seeing accompanying drawing 7) such as come off.
Embodiment 9
(the support blood vessel diameter is than being 1.2-1.3: the compound FirebirdTM of rapamycin estradiol 1) forms the coronary artery injury model, and compares with the rapamycin FirebirdTM to implant overdistension at the miniature pig coronary artery.Postoperative the 14th day and the 30th day check coronary arteriography, histopathology is measured inner membrance area, inner membrance average thickness and the support endothelialization of support vessel segment. and the result shows: effect aspect and rapamycin FirebirdTM that the compound FirebirdTM of rapamycin estradiol suppresses neointimal hyperplasia relatively do not have significant difference (P＞0.05), but its support endothelialization degree in each time period significantly is better than rapamycin FirebirdTM (P＜0.05), sees Fig. 8～11.
Claims (11)
1. a bracket for eluting medicament is characterized in that the active component that this bracket for eluting medicament is loaded with is a kind of drug regimen, and this drug regimen is formed by having the bioactive medicine of estrogen and one or more coagents.
2. according to the described bracket for eluting medicament of claim 1, it is characterized in that the described bioactive medicine of estrogen that has, comprise the estrogen that is selected from natural half-natural source, semi-synthetic and synthetic, as estradiol, estriol, estrone, estradiol benzoate, estradiol valerate, dipropionate estradiol, nilestriol, ethinylestradiol, female three methyl ethers of alkynes, ethinylestradiol methyl ether, diethylstilbestrol and structural derivative and analog; Comprise that also plant origin has the medicine of estrogen activity, as resveratrol, soybean isoflavone, Radix Puerariae flavone and structural derivative thereof and analog.
3. according to the described bracket for eluting medicament of claim 1, it is characterized in that described coagent is selected from one or more of following various kinds of drug active component: immunosuppressant and anti-inflammatory drug, antithrombotic and anticoagulant, antiproliferative agents medicine, short endothelialization medicine again, anti-migration medicine and intercellular matrix regulator.
4. according to the arbitrary described bracket for eluting medicament of claim 1～3, it is characterized in that this bracket for eluting medicament is the medication coat metal rack, its metal material is selected from cobalt, tantalum, Nitinol, nitinol, medical stainless steel.
5. according to the arbitrary described bracket for eluting medicament of claim 1～3, it is characterized in that this bracket for eluting medicament is a Biodegradable scaffold, its composition material is selected from one or more in polyester, poly-anhydride, polyamino acid, poly phosphazene, poly-polysaccharide material or its mixture.
6. according to the described bracket for eluting medicament of claim 4～5, it is characterized in that the medication coat of this bracket for eluting medicament is made up of medicine and polymer support.
7. bracket for eluting medicament according to claim 4 is characterized in that the medication coat of this bracket for eluting medicament does not contain polymer support, directly is distributed in the shrinkage pool of metal rack rack surface or rack surface.
8. bracket for eluting medicament according to claim 6, the polymer support that it is characterized in that this bracket for eluting medicament is a Biostatic polymer, be selected from polyurethanes, polyolefin, polyester, polyamide, polycaprolactam, polyimides, polyvinyl methyl ether, polyvinyl alcohol or vinyl alcohol, olefin copolymer, polyacrylonitrile, polydimethylsiloxane, poly-(ethylene-vinyl acetate), polymer or copolymer based on acrylate, polyvinylpyrrolidone, fluorinated polymer, cellulose esters, the porous ceramics coating, fluorine gathers charcoal, or one or more of its mixture.
9. bracket for eluting medicament according to claim 6 is characterized in that the polymer support of this bracket for eluting medicament is a biological degradation polyalcohol, is selected from polyester, poly-anhydride, polyamino acid, poly phosphazene, poly-polysaccharide, or one or more of its mixture.
10. as the arbitrary described bracket for eluting medicament of claim 1～9, its feature can adopt following any preparation method that medicine and biocompatible materials are mixed or be attached to support: 1) medicine and polymer are dissolved in and obtain medicine and mixture of polymers in single solvent or the mixed solvent, be applied to rack surface by methods such as spraying, dip-coating, brushings, treat to obtain being embedded in after the solvent evaporates medication coat of medicine; 2) medicine is participated in the degradable polymer, adopt the preparation of heating and melting or other method to contain the degradable FirebirdTM of drug regimen; 3) medicine is inserted in the shrinkage pool of rack surface; 4) medicine is mixed in the coatings such as biocompatibility porous ceramics coating, the poly-charcoal of fluorine; 5) pharmaceutical chemistry is attached to polymer or rack surface, relates to the method for chemical derivatization; 6) prepare polymer coating earlier, again medicine is adsorbed onto in the coating, obtain containing the coating of medicine.
11., it is characterized in that this bracket for eluting medicament is used to prevent intravascular stent implantation and the generation of percutaneous arteria coronaria molding postoperative restenosis and promotes the postoperative intravascular stent process of endothelialization again as the arbitrary described bracket for eluting medicament of claim 1～10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101193257A CN101195048A (en) | 2006-12-08 | 2006-12-08 | Compound medicament washing bracket and method for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101193257A CN101195048A (en) | 2006-12-08 | 2006-12-08 | Compound medicament washing bracket and method for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101195048A true CN101195048A (en) | 2008-06-11 |
Family
ID=39545791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101193257A Pending CN101195048A (en) | 2006-12-08 | 2006-12-08 | Compound medicament washing bracket and method for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101195048A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258805A (en) * | 2010-05-28 | 2011-11-30 | 重庆润泽医疗器械有限公司 | Medical metal implanted material porous niobium and preparation method thereof |
| CN102462862A (en) * | 2010-11-17 | 2012-05-23 | 重庆润泽医疗器械有限公司 | Preparation method for porous tantalum serving as medical metal implant material |
| CN102475903A (en) * | 2010-11-29 | 2012-05-30 | 重庆润泽医疗器械有限公司 | Preparation method for medical metal implant material porous niobium |
| CN102475904A (en) * | 2010-11-29 | 2012-05-30 | 重庆润泽医疗器械有限公司 | Preparation method of medical porous metal implant material |
| CN104027849A (en) * | 2014-06-30 | 2014-09-10 | 四川大学 | Soy isoflavone supported biological composite material porous scaffold and preparation |
| CN105771005A (en) * | 2016-03-24 | 2016-07-20 | 乐普（北京）医疗器械股份有限公司 | Anti-rheumatic blood vessel stenosis drug-eluting stent and preparation method and application thereof |
| CN113289072A (en) * | 2021-05-24 | 2021-08-24 | 哈尔滨医科大学 | Liquid medicine for stent, medicine eluting stent and preparation method thereof |
| CN116712620A (en) * | 2023-04-27 | 2023-09-08 | 雅伦生物科技(北京)有限公司 | Drug coating, drug eluting stent containing same and preparation method thereof |
-
2006
- 2006-12-08 CN CNA2006101193257A patent/CN101195048A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258805B (en) * | 2010-05-28 | 2016-08-10 | 温州智创科技有限公司 | medical metal implant material porous niobium and preparation method thereof |
| CN102258805A (en) * | 2010-05-28 | 2011-11-30 | 重庆润泽医疗器械有限公司 | Medical metal implanted material porous niobium and preparation method thereof |
| CN102462862B (en) * | 2010-11-17 | 2013-10-09 | 重庆润泽医药有限公司 | Preparation method for porous tantalum serving as medical metal implant material |
| CN102462862A (en) * | 2010-11-17 | 2012-05-23 | 重庆润泽医疗器械有限公司 | Preparation method for porous tantalum serving as medical metal implant material |
| CN102475904A (en) * | 2010-11-29 | 2012-05-30 | 重庆润泽医疗器械有限公司 | Preparation method of medical porous metal implant material |
| CN102475903B (en) * | 2010-11-29 | 2013-09-18 | 重庆润泽医药有限公司 | Preparation method for medical metal implant material porous niobium |
| CN102475904B (en) * | 2010-11-29 | 2013-09-18 | 重庆润泽医药有限公司 | Preparation method of medical porous metal implant material |
| CN102475903A (en) * | 2010-11-29 | 2012-05-30 | 重庆润泽医疗器械有限公司 | Preparation method for medical metal implant material porous niobium |
| CN104027849A (en) * | 2014-06-30 | 2014-09-10 | 四川大学 | Soy isoflavone supported biological composite material porous scaffold and preparation |
| CN104027849B (en) * | 2014-06-30 | 2016-02-10 | 四川大学 | Carry Biocomposite material porous support and the preparation of soybean isoflavone |
| CN105771005A (en) * | 2016-03-24 | 2016-07-20 | 乐普（北京）医疗器械股份有限公司 | Anti-rheumatic blood vessel stenosis drug-eluting stent and preparation method and application thereof |
| CN113289072A (en) * | 2021-05-24 | 2021-08-24 | 哈尔滨医科大学 | Liquid medicine for stent, medicine eluting stent and preparation method thereof |
| CN116712620A (en) * | 2023-04-27 | 2023-09-08 | 雅伦生物科技(北京)有限公司 | Drug coating, drug eluting stent containing same and preparation method thereof |
| CN116712620B (en) * | 2023-04-27 | 2023-12-12 | 雅伦生物科技(北京)有限公司 | Drug coating, drug eluting stent containing same and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5636451B2 (en) | Drug sustained release stent | |
| CN104623740B (en) | A kind of medicinal balloon and preparation method thereof | |
| US20050180919A1 (en) | Stent with radiopaque and encapsulant coatings | |
| KR102410365B1 (en) | Drug-eluting stents that enable the repair of functional endothelial cell layers and methods of use thereof | |
| CN101195048A (en) | Compound medicament washing bracket and method for preparing the same | |
| CN109715224B (en) | Polymer-free drug-eluting vascular stent | |
| CN101081316A (en) | Novel medicine eluting supporting stand | |
| CN101007187B (en) | A kind of preparation method of composite drug-eluting stent and drug coating thereof | |
| JP7200412B2 (en) | drug-eluting stent | |
| Kim et al. | Development of a biodegradable sirolimus-eluting stent coated by ultrasonic atomizing spray | |
| CN112263360A (en) | In vivo drug eluting stent and preparation method thereof | |
| KR20150137566A (en) | Consecutive Drug releaseing stent for restenosis and inflammatory regulation and manufacturing method thereof | |
| JP5597625B2 (en) | Drug eluting stent | |
| KR102409251B1 (en) | Drug-eluting stent | |
| CN101496813A (en) | Anti-tissue proliferation (vascular restenosis) compositions and methods of use | |
| JP2015154921A (en) | drug sustained-release stent | |
| RU2810457C2 (en) | Implantable device with increased drug delivery area | |
| Lim et al. | Optimal coating method for a dual-layer stent with sirolimus and alpha-lipoic acid in a porcine coronary restenosis model | |
| WO2004002548A1 (en) | Use of organic compounds | |
| Habib et al. | CONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080611 |